ID29930A - Senyawa-senyawa triazol dan penggunaannya - Google Patents

Senyawa-senyawa triazol dan penggunaannya

Info

Publication number
ID29930A
ID29930A IDW00200101733A ID20011733A ID29930A ID 29930 A ID29930 A ID 29930A ID W00200101733 A IDW00200101733 A ID W00200101733A ID 20011733 A ID20011733 A ID 20011733A ID 29930 A ID29930 A ID 29930A
Authority
ID
Indonesia
Prior art keywords
compounds
dopamine
triazol compounds
triazol
formulawhere
Prior art date
Application number
IDW00200101733A
Other languages
English (en)
Indonesian (id)
Inventor
Dorothea Starck
Hans-Jorg Treiber
Liliane Unger
Barbara Neumann-Schultz
Kai Blumbach
Dietmar Schobel
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ID29930A publication Critical patent/ID29930A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IDW00200101733A 1999-01-12 2000-01-12 Senyawa-senyawa triazol dan penggunaannya ID29930A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19900811 1999-01-12

Publications (1)

Publication Number Publication Date
ID29930A true ID29930A (id) 2001-10-25

Family

ID=7894006

Family Applications (2)

Application Number Title Priority Date Filing Date
IDW00200101733A ID29930A (id) 1999-01-12 2000-01-12 Senyawa-senyawa triazol dan penggunaannya
IDW00200101681A ID29552A (id) 1999-01-12 2000-01-12 Senyawa-senyawa triazola dan penggunaannya

Family Applications After (1)

Application Number Title Priority Date Filing Date
IDW00200101681A ID29552A (id) 1999-01-12 2000-01-12 Senyawa-senyawa triazola dan penggunaannya

Country Status (28)

Country Link
US (3) US6579892B1 (ko)
EP (3) EP1140908B1 (ko)
JP (3) JP2002534521A (ko)
KR (3) KR100730667B1 (ko)
CN (3) CN1267430C (ko)
AR (3) AR022228A1 (ko)
AT (3) ATE449768T1 (ko)
AU (3) AU772948B2 (ko)
BG (2) BG65105B1 (ko)
BR (2) BR0007504A (ko)
CA (3) CA2359942A1 (ko)
CO (3) CO5150227A1 (ko)
CZ (2) CZ303926B6 (ko)
DE (3) DE50015802D1 (ko)
ES (2) ES2334326T3 (ko)
HK (1) HK1045311B (ko)
HR (1) HRP20010590A2 (ko)
HU (2) HUP0200709A3 (ko)
ID (2) ID29930A (ko)
IL (3) IL144136A0 (ko)
NO (2) NO20013444D0 (ko)
NZ (2) NZ512830A (ko)
PL (2) PL200238B1 (ko)
SK (2) SK9852001A3 (ko)
TR (2) TR200102025T2 (ko)
TW (1) TWI274750B (ko)
WO (3) WO2000042038A1 (ko)
ZA (2) ZA200106584B (ko)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
AU761018B2 (en) 1998-10-08 2003-05-29 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
AU2001256733A1 (en) * 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
HUP0302264A2 (hu) 2000-11-14 2003-11-28 Smithkline Beecham P.L.C. Dopamin D3 receptorok modulátoraiként felhasználható tetrahidrobenzazepin-származékok és ezeket tartalmazó gyógyszerkészítmények
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
WO2003062205A1 (en) * 2001-12-21 2003-07-31 Smithkline Beecham P.L.C. 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
DE10304870A1 (de) * 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
ATE397755T1 (de) * 2003-03-17 2008-06-15 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2005051945A1 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Heterocyclic compounds as modulators of peroxisome proliferator activated receptors, useful for the treatment and/or prevention of disorders modulated by a ppar
KR20050054084A (ko) * 2003-12-03 2005-06-10 한국전자통신연구원 수신 환경에 기반한 위성 상태 데이터 분배 기능을 가지는위성관제 시스템 및 그 방법
ATE451364T1 (de) * 2004-02-23 2009-12-15 Glaxo Group Ltd Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
JP2007527890A (ja) * 2004-03-08 2007-10-04 グラクソ　グループ　リミテッド ドーパミンｄ３受容体のモジュレーター（抗精神病剤）としてのテトラヒドロベンゾアゼピン誘導体
WO2005090320A2 (en) * 2004-03-12 2005-09-29 Wyeth Triazole derivatives and method of using the same to treat hiv infections
GB0412314D0 (en) 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
GB0413879D0 (en) * 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
GB0414795D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
ATE452134T1 (de) * 2004-08-09 2010-01-15 Abbott Gmbh & Co Kg Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen
EP1784390A2 (en) * 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
ES2417488T3 (es) 2004-12-02 2013-08-08 Abbott Gmbh & Co. Kg Compuestos de triazol adecuados para tratar trastornos que responden a la modulación del receptor de dopamina D3
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) * 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
EP1928846B1 (en) 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US7799815B2 (en) 2005-08-22 2010-09-21 Glaxo Group Limited Triazole derivatives as modulators of dopamine D3 receptors
WO2007028145A2 (en) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
WO2008097640A2 (en) 2007-02-08 2008-08-14 Synta Pharmaceuticals Corp. Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
US8106083B2 (en) * 2008-08-08 2012-01-31 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
US8829001B2 (en) 2008-10-10 2014-09-09 The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
US9326955B2 (en) * 2008-10-31 2016-05-03 Loyola University Chicago Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions
EP2516446B1 (en) * 2009-12-22 2014-08-13 Cephalon, Inc. Substituted hexahydrochromeno[3,4-b]pyrroles with affinity for the serotonin receptor (5-ht) family
US9035059B2 (en) * 2011-03-14 2015-05-19 Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound
EA201492069A1 (ru) * 2012-05-30 2015-03-31 Ф.Хоффманн-Ля Рош Аг Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
RU2561063C1 (ru) * 2014-07-01 2015-08-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Способ коррекции неврологических нарушений при хронической алкогольной интоксикации
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034673A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Tetrahydroisoquinoline derived prmt5-inhibitors
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
WO2018209267A2 (en) * 2017-05-12 2018-11-15 Board Of Trustees Of The Southern Illinois University On Behalf Of Southern Illinois University Edwardsville 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
US10941153B2 (en) * 2018-05-31 2021-03-09 Regents Of The University Of Minnesota Substituted phenethylamine derivatives
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338453A (en) * 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4408049A (en) 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
JP3155276B2 (ja) 1991-05-20 2001-04-09 ファルマシア・アンド・アップジョン・カンパニー カルボキサミド−（１，２ｎ）−カルボサイクリック−２−アミノテトラリン誘導体
DK0612244T3 (da) 1991-11-05 2002-01-14 Smithkline Beecham Corp Endothelinreceptorantagonister
FR2687146B1 (fr) 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
HU9503067D0 (en) 1993-04-27 1995-12-28 Smithkline Beecham Corp Endotheline receptor antagonists
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
FR2722194B1 (fr) 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent
DE4425144A1 (de) * 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
BR9509760A (pt) * 1994-11-23 1998-06-30 Neurogen Corp Composto
WO1996030333A1 (en) 1995-03-27 1996-10-03 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic agents
AU5272296A (en) 1995-04-06 1996-10-23 Novo Nordisk A/S Benzopyranopyrrole compounds, their preparation and use
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
AU7490496A (en) * 1995-11-10 1997-05-29 Novo Nordisk A/S Enantiomers of cis-benz{e}indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
NZ332477A (en) 1996-05-11 2000-07-28 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
CN1159292C (zh) * 1996-05-31 2004-07-28 法玛西雅厄普约翰美国公司 用作选择性多巴胺d3配体的芳基取代的环胺类化合物
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
EP0922035B1 (en) * 1996-08-14 2001-02-07 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives and their pharmaceutical use
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
CZ194499A3 (cs) 1996-12-06 1999-11-17 Abbott Laboratories Benzopyranopyrolové a benzopyranopyridín alfa-1 adrenergické sloučeniny
FR2760014B1 (fr) * 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) * 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
JP2002501506A (ja) 1997-05-03 2002-01-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ドーパミンｄ▲下３▼受容体のモジュレーターとしてのテトラヒドロイソキノリン誘導体
GB9709303D0 (en) 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710366D0 (en) * 1997-05-20 1997-07-16 Biocompatibles Ltd Stent deployment device
FR2764890B1 (fr) 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion

Also Published As

Publication number Publication date
PL200238B1 (pl) 2008-12-31
EP1144405A1 (de) 2001-10-17
CN1345319A (zh) 2002-04-17
AU772948B2 (en) 2004-05-13
IL144136A (en) 2006-12-10
HUP0200522A2 (en) 2002-06-29
JP2002534520A (ja) 2002-10-15
CN1149209C (zh) 2004-05-12
US6583166B1 (en) 2003-06-24
HK1045311B (zh) 2007-03-30
ID29552A (id) 2001-09-06
SK9862001A3 (en) 2002-04-04
IL144136A0 (en) 2002-05-23
AU2436700A (en) 2000-08-01
WO2000042037A1 (de) 2000-07-20
AR022230A1 (es) 2002-09-04
AR022228A1 (es) 2002-09-04
US6602867B1 (en) 2003-08-05
DE50014472D1 (de) 2007-08-23
NO20013443L (no) 2001-07-12
DE50015802D1 (de) 2010-01-07
CA2359948A1 (en) 2000-07-20
BR0007500A (pt) 2001-10-23
ATE449768T1 (de) 2009-12-15
NO20013443D0 (no) 2001-07-11
EP1140908B1 (de) 2009-03-04
BG105784A (en) 2002-02-28
NZ512830A (en) 2003-08-29
EP1140907B1 (de) 2007-07-11
ES2334326T3 (es) 2010-03-09
TWI274750B (en) 2007-03-01
HUP0200522A3 (en) 2003-05-28
CZ20012551A3 (cs) 2002-03-13
KR100775720B1 (ko) 2007-11-09
NO20013444L (no) 2001-07-11
CA2359952A1 (en) 2000-07-20
ZA200106585B (en) 2002-08-12
KR100687682B1 (ko) 2007-02-28
SK9852001A3 (en) 2002-04-04
EP1144405B1 (de) 2009-11-25
HK1045311A1 (en) 2002-11-22
CO5150182A1 (es) 2002-04-29
NZ512864A (en) 2003-04-29
NO20013444D0 (no) 2001-07-11
AU2289700A (en) 2000-08-01
ZA200106584B (en) 2002-08-12
BG65086B1 (bg) 2007-02-28
CN1267430C (zh) 2006-08-02
BG65105B1 (bg) 2007-02-28
CZ20012550A3 (cs) 2002-02-13
ES2288839T3 (es) 2008-02-01
EP1140908A1 (de) 2001-10-10
HUP0200709A2 (hu) 2002-07-29
HUP0200709A3 (en) 2004-07-28
JP4933694B2 (ja) 2012-05-16
PL201889B1 (pl) 2009-05-29
CA2359942A1 (en) 2000-07-20
ATE366729T1 (de) 2007-08-15
DE50015576D1 (de) 2009-04-16
BG105783A (en) 2002-03-29
WO2000042036A1 (de) 2000-07-20
KR20010086470A (ko) 2001-09-12
ATE424398T1 (de) 2009-03-15
JP2002534521A (ja) 2002-10-15
CO5150227A1 (es) 2002-04-29
BR0007504A (pt) 2001-10-02
HRP20010590A2 (en) 2003-08-31
KR100730667B1 (ko) 2007-06-21
JP2002534519A (ja) 2002-10-15
WO2000042038A1 (de) 2000-07-20
US6579892B1 (en) 2003-06-17
IL144137A0 (en) 2002-05-23
PL349841A1 (en) 2002-09-23
AU2541200A (en) 2000-08-01
KR20010086471A (ko) 2001-09-12
AR022229A1 (es) 2002-09-04
EP1140907A1 (de) 2001-10-10
KR20070032830A (ko) 2007-03-22
JP4615125B2 (ja) 2011-01-19
CN1347414A (zh) 2002-05-01
CN1345318A (zh) 2002-04-17
CZ303926B6 (cs) 2013-06-26
TR200102026T2 (tr) 2001-12-21
AU773047B2 (en) 2004-05-13
CA2359948C (en) 2010-09-21
CO5150224A1 (es) 2002-04-29
PL350246A1 (en) 2002-12-02
TR200102025T2 (tr) 2002-05-21

Similar Documents

Publication Publication Date Title
ID29930A (id) Senyawa-senyawa triazol dan penggunaannya
TR200000009T2 (tr) Triazol bileşikleri ve bunların dopamin-D3-ligandları olarak kullanımları.
UA34466C2 (uk) Засіб для несистемної боротьби з паразитуючими комахами
PT935465E (pt) Compostos novos de imidazole substituido
NO970162D0 (no) Substituerte pyrimidinforbindelser og anvendelse derav
MX9805628A (es) Imidazoles novedosos substituidos con cicloalquilo.
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
BR9706973A (pt) Novos compostos de imidazol substituídos
TR200200068T2 (tr) Nematisital triflüorobütenler
WO2003105840A3 (en) Sphingosine kinase inhibitors
TR200000014T2 (tr) Yeni ikameli imidazol bileşimleri.
MY116478A (en) Tri-substituted imidazoles having multiple therapeutic properties
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
BG101113A (bg) Триазолови съединения и тяхното използване
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
DE60011677D1 (en) Tryptase-inhibitoren
DK1244614T3 (da) Tryptase-inhibitorer
TR200003083T2 (tr) CNS hastalıklarının tedavisi için paroxetine 10-camphorsulfonate.
TR199902914T2 (xx) �zole sistolik hipertansiyonu tedavi y�ntemi.
BG102613A (en) New substituted imidazoles
MX9700125A (es) Compuestos de pirimidina.